{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:16:05Z","timestamp":1790291765346,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Mashhad University of Medical Sciences, Mashhad, Iran","award":["940492"],"award-info":[{"award-number":["940492"]}]},{"DOI":"10.13039\/501100012155","name":"National Institute for Medical Research Development","doi-asserted-by":"publisher","award":["963401"],"award-info":[{"award-number":["963401"]}],"id":[{"id":"10.13039\/501100012155","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.atherosclerosis.2019.02.001","type":"journal-article","created":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T04:18:41Z","timestamp":1550117921000},"page":"69-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"special_numbering":"C","title":["Long-term generation of antiPCSK9 antibody using a nanoliposome-based vaccine delivery system"],"prefix":"10.1016","volume":"283","author":[{"given":"Amir Abbas","family":"Momtazi-Borojeni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud Reza","family":"Jaafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Badiee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib1","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1194\/jlr.R026658","article-title":"The PCSK9 decade thematic review series: new lipid and lipoprotein targets for the treatment of cardiometabolic diseases","volume":"53","author":"Lambert","year":"2012","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib2","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1194\/jlr.M700071-JLR200","article-title":"Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis","volume":"48","author":"Qian","year":"2007","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib3","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/326760a0","article-title":"Acid-dependent ligand dissociation and recycling of LDL receptor mediated by growth factor homology region","volume":"326","author":"Davis","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib4","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1126\/science.1078124","article-title":"Structure of the LDL receptor extracellular domain at endosomal pH","volume":"298","author":"Rudenko","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib5","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1042\/bj2770677","article-title":"Deletion of two growth-factor repeats from the low-density-lipoprotein receptor accelerates its degradation","volume":"277","author":"Van der Westhuyzen","year":"1991","journal-title":"Biochem. J."},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib6","doi-asserted-by":"crossref","first-page":"18602","DOI":"10.1074\/jbc.M702027200","article-title":"Binding of proprotein convertase subtilisin\/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation","volume":"282","author":"Zhang","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib7","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1073\/pnas.0712064105","article-title":"Molecular basis for LDL receptor recognition by PCSK9","volume":"105","author":"Kwon","year":"2008","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.atherosclerosis.2013.01.044","article-title":"The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway","volume":"228","author":"Catapano","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11886-012-0345-z","article-title":"PCSK9 Inhibitors: potential in cardiovascular therapeutics","volume":"15","author":"Do","year":"2013","journal-title":"Curr. Cardiol. Rep."},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib10","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10557-013-6479-4","article-title":"New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect?","volume":"27","author":"Sahebkar","year":"2013","journal-title":"Cardiovasc. Drugs Ther"},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib11","series-title":"FDA Approves Praluent to Treat Certain Patients with High Cholesterol","author":"Food","year":"2015"},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib12","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib13","series-title":"FDA Approves Repatha to Treat Certain Patients with High Cholestero L","author":"Food","year":"2015"},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib14","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib15","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.2016.11004","article-title":"Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease","volume":"316","author":"Kazi","year":"2016","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114469","article-title":"Peptide-based anti-PCSK9 vaccines-an approach for long-term LDLc management","volume":"9","author":"Galabova","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib17","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1194\/jlr.M028340","article-title":"Immunization against proprotein convertase subtilisin-like\/kexin type 9 lowers plasma LDL-cholesterol levels in mice","volume":"53","author":"Fattori","year":"2012","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib18","doi-asserted-by":"crossref","first-page":"5747","DOI":"10.1016\/j.vaccine.2015.09.044","article-title":"A cholesterol-lowering VLP vaccine that targets PCSK9","volume":"33","author":"Crossey","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib19","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1042\/BJ20082407","article-title":"Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor","volume":"419","author":"Duff","year":"2009","journal-title":"Biochem. J."},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib20","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.str.2007.04.004","article-title":"The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol","volume":"15","author":"Piper","year":"2007","journal-title":"Structure"},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib21","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s12603-009-0070-5","article-title":"Development of AFFITOPE vaccines for Alzheimer's disease (AD)\u2014from concept to clinical testing","volume":"13","author":"Schneeberger","year":"2009","journal-title":"JNHA-The Journal of Nutrition, Health and Aging"},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib22","first-page":"3012","article-title":"Phase I trial of a melanoma vaccine with gp100280\u2013288 peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes","volume":"7","author":"Slingluff","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib23","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2217\/nnm.13.66","article-title":"Liposomes containing NY-ESO-1\/tetanus toxoid and adjuvant peptides targeted to human dendritic cells via the Fc receptor for cancer vaccines","volume":"9","author":"Cruz","year":"2014","journal-title":"Nanomedicine"},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib24","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0021-9258(18)70226-3","article-title":"Phosphorus assay in column chromatography","volume":"234","author":"Bartlett","year":"1959","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib25","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"Jama"},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib26","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s40273-018-0671-0","article-title":"Are PCSK9 inhibitors cost effective?","volume":"36","author":"Korman","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib27","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrd1284","article-title":"Therapeutic vaccination for chronic diseases: a new class of drugs in sight","volume":"3","author":"Bachmann","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib28","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MOL.0000000000000312","article-title":"Vaccine strategies for lowering LDL by immunization against proprotein convertase subtilisin\/kexin type 9","volume":"27","author":"Chackerian","year":"2016","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib29","first-page":"286","article-title":"The renin-angiotensin system and therapeutic vaccines for hypertension","volume":"9","author":"Zhu","year":"2008","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1750-3639.2004.tb00493.x","article-title":"Neuropathology and pathogenesis of encephalitis following amyloid \u03b2 immunization in Alzheimer's disease","volume":"14","author":"Ferrer","year":"2004","journal-title":"Brain Pathol."},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib31","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41541-018-0060-x","article-title":"Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica","volume":"3","author":"Abhyankar","year":"2018","journal-title":"npj Vaccines"},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185099","article-title":"Conjugated nanoliposome with the HER2\/neu-derived peptide GP2 as an effective vaccine against breast cancer in mice xenograft model","volume":"12","author":"Razazan","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib33","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.1002\/jcp.26361","article-title":"Nanoliposomes as the adjuvant delivery systems in cancer immunotherapy","volume":"233","author":"Zamani","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib34","series-title":"Potential of Cationic Liposomes as Adjuvants\/Delivery Systems for Tuberculosis Subunit Vaccines, Reviews of Physiology, Biochemistry and Pharmacology","author":"Khademi","year":"2018"},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib35","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s12026-017-8969-0","article-title":"Lambda phage nanoparticles displaying HER2-derived E75 peptide induce effective E75-CD8+ T response","volume":"66","author":"Arab","year":"2018","journal-title":"Immunol. Res."},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib36","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1021\/mp200016d","article-title":"Negatively charged liposomes show potent adjuvant activity when simply admixed with protein antigens","volume":"8","author":"Yanasarn","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib37","series-title":"Adjuvancy of Negatively-Charged Liposomes for Pulmonary Delivery of Vaccines, Pulmonary Delivery of Liposome-Based Vaccines: Application to a Murine Model of Schistosoma Mansoni Infection","first-page":"32","author":"Gameiro","year":"2008"},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib38","first-page":"25","article-title":"Comparison of the immune response against polio peptides covalently-surface-linked to and internally-entrapped in liposomes","volume":"9","author":"Tan","year":"1991","journal-title":"Asian Pac. J. Allergy Immunol."},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib39","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/0264-410X(90)90008-A","article-title":"Liposomal vaccine: influence of antigen association on the kinetics of the humoral response","volume":"8","author":"Th\u00e9rien","year":"1990","journal-title":"Vaccine"},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib40","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/0264-410X(94)90183-X","article-title":"Correlation between in vitro and in vivo behaviour of liposomal antigens","volume":"12","author":"Shahum","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib41","series-title":"Antibody Responses to Liposome-Associated Antigen","author":"Vannier","year":"1988"},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib42","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1021\/bc970183n","article-title":"Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses","volume":"9","author":"Guan","year":"1998","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.atherosclerosis.2019.02.001_bib43","doi-asserted-by":"crossref","first-page":"12534","DOI":"10.1038\/s41598-017-13069-w","article-title":"A therapeutic peptide vaccine against PCSK9","volume":"7","author":"Pan","year":"2017","journal-title":"Sci. Rep."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915019300632?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915019300632?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T16:37:14Z","timestamp":1694623034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915019300632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":43,"alternative-id":["S0021915019300632"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.02.001","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term generation of antiPCSK9 antibody using a nanoliposome-based vaccine delivery system","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}